Think these are examples of ultra net worth people’s investments being good for everyone over time:
Altos Labs: The Future of Cellular Rejuvenation
As Altos Labs CEO & Founder Hal Barron, MD, eloquently states:
“We now have pre-clinical data suggesting that the cellular dysfunction associated with ageing and disease can be reversible. This knowledge means that it may, one day, be possible to transform patients’ lives by reversing disease, injury and the disabilities that can occur throughout life.”
In a move that sent shockwaves through the scientific community, Altos Labs launched in 2022 with an astonishing $3 billion in funding, backed by visionary billionaires Jeff Bezos and Yuri Milner.
The company’s innovative approach is structured around two key entities: the Altos Institutes of Science, dedicated to exploring deep scientific questions and integrating findings into a collaborative research effort, and the Altos Institutes of Medicine, focused on translating knowledge about cell health and programming into transformative medicines.
Armed with this substantial funding, Altos Labs has set its sights on an ambitious mission: to restore cell health and resilience through cellular rejuvenation programming, with the ultimate goal of reversing disease, injury, and age-related disabilities.
To achieve this monumental task, the company has assembled a star-studded lineup of the world’s most brilliant minds in science and research.
Among the luminaries at Altos Labs are four Nobel laureates: Frances Arnold, PhD (2018 Chemistry), David Baltimore, PhD (1975 Medicine), Jennifer Doudna, PhD (2020 Chemistry), and Shinya Yamanaka, MD, PhD (2012 Medicine).
The company has also recruited longevity expert Dr. Steve Horvath, renowned for his groundbreaking work on epigenetic clocks, and Juan Carlos Izpisua Belmonte, PhD, who built upon Yamanaka’s findings in 2016 by demonstrating the possibility of “partial” cellular reprogramming.
Altos Labs’ initial focus is to empower its scientists and researchers to unravel the mysteries of rejuvenation.* This includes investigating how to tailor reprogramming to rejuvenate animals without fatal consequences and exploring the potential of ordinary drugs as an alternative to genetic engineering.
NewLimit: Reversing Cellular Aging
NewLimit, co-founded by Coinbase CEO Brian Armstrong and venture capitalist Blake Byers, PhD, is taking a bold approach to tackle aging at the cellular level.
But how exactly will they achieve this ambitious goal?
NewLimit’s unique approach lies in the development of epigenetic reprogramming medicines.
as Brian Armstrong puts it:
“Think of how many dollars are spent trying to figure out treatments for major diseases, most of which are in some way correlated to aging … It would be a huge success if you could wipe out even one of those disease categories, so think about how exciting it is to go after something even more fundamental.”
Retro Bio’s Mission: Extending Human Healthspan by 10 Years
With $180 million in investment secured from OpenAI CEO Sam Altman, Retro Bio emerged from stealth mode in 2022 with a mission to add 10 years to healthy human lifespan by targeting the cellular drivers of aging
Retro Bio currently has five discovery programs aimed at reversing cellular aging, with two programs, autophagy and in vivo reprogramming, conducted directly in the body.
The other three programs, including T cell and hematopoietic stem cell reprogramming and microglia therapeutics, involve reprogramming cells in the lab and returning rejuvenated cells to the body through a process the company calls “micro replacement.”
In a significant development, Retro Bio recently announced an $85 million partnership with Multiply Labs to enhance the production of its cell therapies targeting age-related diseases.
From
May 26, 2024
Billionaires Investing in Longevity?